Search

Your search keyword '"Trailor, Michael A."' showing total 6 results
Start Over Author "Trailor, Michael A."
6 results on '"Trailor, Michael A."'

1. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood

Author

Lee, Won‐Ho, primary, Graham, Charlotte E., additional, Wiggin, Hadley R., additional, Nolan, Hannah K., additional, Graham, Kiana J., additional, Korell, Felix, additional, Leick, Mark B., additional, Barselau, Alexis L., additional, Emmanuel‐Alejandro, Estelle, additional, Trailor, Michael A., additional, Gildea, Juliane M., additional, Preffer, Frederic, additional, Frigault, Matthew J., additional, Maus, Marcela V., additional, and Gallagher, Kathleen M. E., additional

Published
2024
Full Text
View/download PDF

2. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CARin peripheral blood

Author

Lee, Won‐Ho, Graham, Charlotte E., Wiggin, Hadley R., Nolan, Hannah K., Graham, Kiana J., Korell, Felix, Leick, Mark B., Barselau, Alexis L., Emmanuel‐Alejandro, Estelle, Trailor, Michael A., Gildea, Juliane M., Preffer, Frederic, Frigault, Matthew J., Maus, Marcela V., and Gallagher, Kathleen M. E.

Abstract

Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there are limited options for reliable BCMA CAR T detection assays for physicians and researchers looking to explore it as a biomarker for clinical outcome. Given the known association of CAR T cell expansion kinetics with toxicity and response, being able to quantify BCMA CAR T cells routinely and accurately in the blood of patients can serve as a valuable asset. Here, we optimized an accurate and sensitive flow cytometry test using a PE‐conjugated soluble BCMA protein, with a lower limit of quantitation of 0.19% of CD3+ T cells, suitable for use as a routine assay for monitoring the frequency of BCMA CAR T cells in the blood of patients receiving either ciltacabtagene autoleucel or idecabtagene vicleucel.

Published
2024
Full Text
View/download PDF

3. CAR-T Cell Therapy in Recurrent Primary CNS Lymphoma (PCNSL): A Phase 2 Clinical Trial (S27.009)

Author

Dietrich, Jorg, primary, Chen, Yi-Bin, additional, Gallagher, Kathleen, additional, Jordan, Justin, additional, Forst, Deborah, additional, Plotkin, Scott, additional, Lindell, Kevin, additional, Cook, Daniella, additional, Depinho, Gabriel, additional, Trailor, Michael, additional, Batchelor, Tracy, additional, Maus, Marcela, additional, and Frigault, Matthew, additional

Published
2022
Full Text
View/download PDF

4. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

Author

Wehrli, Marc, primary, Gallagher, Kathleen, additional, Chen, Yi-Bin, additional, Leick, Mark B, additional, McAfee, Steven L, additional, El-Jawahri, Areej R, additional, DeFilipp, Zachariah, additional, Horick, Nora, additional, O'Donnell, Paul, additional, Spitzer, Thomas, additional, Dey, Bimal, additional, Cook, Daniella, additional, Trailor, Michael, additional, Lindell, Kevin, additional, Maus, Marcela V, additional, and Frigault, Matthew J, additional

Published
2022
Full Text
View/download PDF

5. A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Author

Frigault, Matthew J., primary, Gallagher, Kathleen M.E., additional, Wehrli, Marc, additional, Valles, Betsy, additional, Casey, Keagan, additional, Lindell, Kevin, additional, Trailor, Michael, additional, Cho, Hana, additional, Brown, Jami L., additional, Horick, Nora K., additional, Chou, Justin, additional, Shen, Rhine R., additional, Filosto, Simone, additional, Bot, Adrian, additional, and Maus, Marcela V., additional

Published
2021
Full Text
View/download PDF

6. Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma

Author

Frigault, Matthew J., primary, Dietrich, Jorg, additional, Gallagher, Kathleen M.E., additional, Scarfò, Irene, additional, Roschewski, Mark, additional, Jordan, Justin T, additional, Forst, Deborah A., additional, Plotkin, Scott R, additional, Cook, Daniella, additional, Casey, Keagan, additional, Katsis, Katelin, additional, Lindell, Kevin, additional, Trailor, Michael, additional, Horick, Nora, additional, McAfee, Steven, additional, O'Donnell, Paul V, additional, Spitzer, Thomas R, additional, Dey, Bimalangshu R, additional, Defilipp, Zachariah, additional, El-Jawahri, Areej, additional, Batchelor, Tracy, additional, Maus, Marcela V., additional, and Chen, Yi-Bin, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results